Capricor Therap (CAPR)

$10.05 +0.80 (8.65%)
Market Cap 422.51M
Revenue (ttm) 22.27M
Net Income (ttm) -40.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 19.78
Profit Margin -181.72%
Debt to Equity Ratio 0.00
Volume 3,455,900
Avg Vol 2,868,710
Day's Range N/A - N/A
Shares Out 45.68M
Stochastic %K 50%
Beta 0.84
Analysts Strong Sell
Price Target $39.50

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 727 1755
Address:
10865 Road to the Cure, Suite 150, San Diego, United States
wallstengine
wallstengine Jun. 26 at 7:32 AM
B. Riley Initiates Coverage on $CAPR with Buy Rating, PT $21; says Deramiocel shows promise in DMD-cardiomyopathy with potential near-term catalyst Analyst comments: "DeramioceI could become the first therapy for Duchenne Muscular Dystrophy-cardiomyopathy addressing the leading cause of mortality in DMD. The Phase II data demonstrated clinically meaningful preservation of cardiac function through 4 years, including left ventricular ejection fraction (LVEF) improvement of 1.9% and 1.2% at 24 and 36 months. We believe investors may have over-weighted regulatory risk related to FDA disruption and the on-again, off-again AdCom that may reflect the emergence of a more flexible, rare disease-focused agency that benefits Deramiocel as the only safe and potential disease-modifying option. We acknowledge perceived risks from relying on Phase II data heading into the August PDUFA but note that the fully enrolled Phase III may address any perceived weakness in the Phase II data package. We believe Phase III will likely replicate the unprecedented Phase II data and note that management is prepared to unblind the fully enrolled Phase III as early as 4Q25 if deemed necessary for approval. Post approval, Deramiocel is expected to operate within a favorable commercial environment that includes a 100–200 patient base representing $25M–$50M in top-line revenue within one quarter of launch." Analyst: Madison El-Saadi
1 · Reply
teddan80
teddan80 Jun. 26 at 6:49 AM
Capricor’s Deramiocel has received Orphan Drug Designation, unlocking key regulatory and commercial advantages that go far beyond symbolic value. It provides seven years of market exclusivity in the US post approval, shielding Deramiocel from direct competition. It also enables tax credits on qualifying clinical trial costs, easing cash burn and reducing the need for dilutive funding. FDA application fees are waived, lowering development costs. Deramiocel is already on the Priority Review and Accelerated Approval tracks, which speeds up the regulatory timeline. If approved, Capricor may also receive a Priority Review Voucher, a tradable asset that has fetched up to 100 million dollars in past transactions. With Deramiocel under FDA priority review and phase 3 data expected soon, Capricor is nearing a pivotal transition from clinical stage to commercial readiness, making it a compelling setup for long term investors
0 · Reply
jimmy18000
jimmy18000 Jun. 26 at 6:19 AM
$CAPR nice to see Pat Furlong really visible on social media supporting Deramiocel and taking time to explain the purpose of an AdCom. She doesn’t usually hit the like button on posts by PPMD, let alone share a post on her feed like she did with CAPR PR here. Wouldn’t be surprised that she and PPMD are proactive with the FDA to approve Deramiocel on time or earlier. Heard she has a direct comm with Prasad.
0 · Reply
graywolf
graywolf Jun. 26 at 5:49 AM
$CAPR Interesting 👇
0 · Reply
hoonyinvests
hoonyinvests Jun. 26 at 4:35 AM
$CAPR you’re saying that we should short this stock and drive the company into bankruptcy because their current treatment extends children’s lives versus curing it. You’re a terrible human being if one at all. I’ve helped treat patients with this disease, and it’s clear you have no empathy. You better hope your family doesn’t get sick.
3 · Reply
HamBoneXoXo
HamBoneXoXo Jun. 26 at 4:21 AM
$CAPR I just reposted the data and my interpretation of it and these are the replies. Sorry that objectivity has died while lowlifes roam throwing insults because the data doesn’t fit their ignorance. I really don’t care less.
1 · Reply
CAPRuccino
CAPRuccino Jun. 26 at 4:06 AM
$CAPR all has been said now just 🦗🦗
0 · Reply
BioCapitalFund
BioCapitalFund Jun. 26 at 3:53 AM
$CAPR Please watch this true story (2 minutes long) of Pat Furlong aired on CBS Chicago 11 years ago from tomorrow. "Pat Furlong started an organization (PPMD) in her two sons' honor to help find a cure for Duchenne muscular dystrophy, the deadly disease that took her two sons." Now... How much longer those moms and their boys should suffer? It is imperative that FDA should approve deramiocel "even one day faster" to prevent more crying moms to lose their precious sons. https://www.youtube.com/watch?v=nQdOJIg8afo (8:53pm, Wednesday, California)
0 · Reply
HamBoneXoXo
HamBoneXoXo Jun. 26 at 3:48 AM
$CAPR Didn’t see much discussion on the four yr hope2 ole data: As shown below; one estimates 0.7 drop in drug effectiveness per yr translating to a drug utility of about 5 or at most 6 yrs continuous yrs. In other words, prescribing for life is not an option here as stabilization effects fade out by yr 6. Any comments?
7 · Reply
Coinbit
Coinbit Jun. 26 at 3:29 AM
$CAPR I am going to be buying every morning 10 shares at opening regardless the price till approval !!!! Shorts bring it on
0 · Reply
Latest News on CAPR
FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy

Jun 24, 2025, 2:51 PM EDT - 1 day ago

FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy

US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy

Jun 24, 2025, 9:16 AM EDT - 1 day ago

US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy

Why Is Capricor Therapeutics Stock Trading Lower On Monday?

Jun 23, 2025, 12:46 PM EDT - 2 days ago

Why Is Capricor Therapeutics Stock Trading Lower On Monday?

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients

Jun 20, 2025, 3:11 PM EDT - 5 days ago

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

Jun 20, 2025, 9:25 AM EDT - 5 days ago

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

Jun 17, 2025, 9:00 AM EDT - 8 days ago

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement

Jun 11, 2025, 5:18 PM EDT - 14 days ago

Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program

Jun 11, 2025, 9:25 AM EDT - 14 days ago

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 3, 2025, 10:00 AM EDT - 22 days ago

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation

Jun 2, 2025, 10:00 AM EDT - 23 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect

Jun 1, 2025, 10:00 AM EDT - 24 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out

May 30, 2025, 10:00 AM EDT - 26 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation

May 29, 2025, 10:00 AM EDT - 27 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Investors to Learn More About the Investigation

May 28, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Investors to Learn More About the Investigation

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 27, 2025, 10:00 AM EDT - 4 weeks ago

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Connect

May 26, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Investors to Inquire about Securities Investigation

May 23, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Investors to Inquire about Securities Investigation

Capricor Therapeutics' Buy Thesis Ahead Of Deramiocel PDUFA Date

May 23, 2025, 2:44 AM EDT - 4 weeks ago

Capricor Therapeutics' Buy Thesis Ahead Of Deramiocel PDUFA Date

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Reach Out

May 22, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Reach Out

Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision

May 22, 2025, 12:45 AM EDT - 5 weeks ago

Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Reach Out

May 21, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Connect

May 20, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Connect

I Missed The Quantum Rally - I Won't Miss The Next One

May 20, 2025, 5:47 AM EDT - 5 weeks ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CLPT EDIT NTLA VANI VERV

CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

May 20, 2025, 5:26 AM EDT - 5 weeks ago

CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 19, 2025, 11:00 AM EDT - 5 weeks ago

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Capricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Conference Call Transcript

May 13, 2025, 8:36 PM EDT - 6 weeks ago

Capricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Conference Call Transcript

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

May 6, 2025, 9:15 AM EDT - 7 weeks ago

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy

May 5, 2025, 11:08 AM EDT - 7 weeks ago

US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

May 5, 2025, 8:00 AM EDT - 7 weeks ago

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 6:56 PM EDT - 3 months ago

Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 19, 2025, 4:05 PM EDT - 3 months ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Mar 17, 2025, 9:25 AM EDT - 3 months ago

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

Mar 10, 2025, 9:13 AM EDT - 3 months ago

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Mar 7, 2025, 9:25 AM EST - 3 months ago

Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Capricor: Further Value Unlocked With Priority Review Of Deramiocel

Mar 4, 2025, 3:57 PM EST - 4 months ago

Capricor: Further Value Unlocked With Priority Review Of Deramiocel

Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition

Mar 4, 2025, 11:21 AM EST - 4 months ago

Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition

Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data

Feb 23, 2025, 9:13 PM EST - 4 months ago

Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Jan 2, 2025, 9:15 AM EST - 6 months ago

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

Dec 12, 2024, 12:08 PM EST - 6 months ago

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

MESO XBI

Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached

Dec 7, 2024, 5:08 AM EST - 7 months ago

Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached

wallstengine
wallstengine Jun. 26 at 7:32 AM
B. Riley Initiates Coverage on $CAPR with Buy Rating, PT $21; says Deramiocel shows promise in DMD-cardiomyopathy with potential near-term catalyst Analyst comments: "DeramioceI could become the first therapy for Duchenne Muscular Dystrophy-cardiomyopathy addressing the leading cause of mortality in DMD. The Phase II data demonstrated clinically meaningful preservation of cardiac function through 4 years, including left ventricular ejection fraction (LVEF) improvement of 1.9% and 1.2% at 24 and 36 months. We believe investors may have over-weighted regulatory risk related to FDA disruption and the on-again, off-again AdCom that may reflect the emergence of a more flexible, rare disease-focused agency that benefits Deramiocel as the only safe and potential disease-modifying option. We acknowledge perceived risks from relying on Phase II data heading into the August PDUFA but note that the fully enrolled Phase III may address any perceived weakness in the Phase II data package. We believe Phase III will likely replicate the unprecedented Phase II data and note that management is prepared to unblind the fully enrolled Phase III as early as 4Q25 if deemed necessary for approval. Post approval, Deramiocel is expected to operate within a favorable commercial environment that includes a 100–200 patient base representing $25M–$50M in top-line revenue within one quarter of launch." Analyst: Madison El-Saadi
1 · Reply
teddan80
teddan80 Jun. 26 at 6:49 AM
Capricor’s Deramiocel has received Orphan Drug Designation, unlocking key regulatory and commercial advantages that go far beyond symbolic value. It provides seven years of market exclusivity in the US post approval, shielding Deramiocel from direct competition. It also enables tax credits on qualifying clinical trial costs, easing cash burn and reducing the need for dilutive funding. FDA application fees are waived, lowering development costs. Deramiocel is already on the Priority Review and Accelerated Approval tracks, which speeds up the regulatory timeline. If approved, Capricor may also receive a Priority Review Voucher, a tradable asset that has fetched up to 100 million dollars in past transactions. With Deramiocel under FDA priority review and phase 3 data expected soon, Capricor is nearing a pivotal transition from clinical stage to commercial readiness, making it a compelling setup for long term investors
0 · Reply
jimmy18000
jimmy18000 Jun. 26 at 6:19 AM
$CAPR nice to see Pat Furlong really visible on social media supporting Deramiocel and taking time to explain the purpose of an AdCom. She doesn’t usually hit the like button on posts by PPMD, let alone share a post on her feed like she did with CAPR PR here. Wouldn’t be surprised that she and PPMD are proactive with the FDA to approve Deramiocel on time or earlier. Heard she has a direct comm with Prasad.
0 · Reply
graywolf
graywolf Jun. 26 at 5:49 AM
$CAPR Interesting 👇
0 · Reply
hoonyinvests
hoonyinvests Jun. 26 at 4:35 AM
$CAPR you’re saying that we should short this stock and drive the company into bankruptcy because their current treatment extends children’s lives versus curing it. You’re a terrible human being if one at all. I’ve helped treat patients with this disease, and it’s clear you have no empathy. You better hope your family doesn’t get sick.
3 · Reply
HamBoneXoXo
HamBoneXoXo Jun. 26 at 4:21 AM
$CAPR I just reposted the data and my interpretation of it and these are the replies. Sorry that objectivity has died while lowlifes roam throwing insults because the data doesn’t fit their ignorance. I really don’t care less.
1 · Reply
CAPRuccino
CAPRuccino Jun. 26 at 4:06 AM
$CAPR all has been said now just 🦗🦗
0 · Reply
BioCapitalFund
BioCapitalFund Jun. 26 at 3:53 AM
$CAPR Please watch this true story (2 minutes long) of Pat Furlong aired on CBS Chicago 11 years ago from tomorrow. "Pat Furlong started an organization (PPMD) in her two sons' honor to help find a cure for Duchenne muscular dystrophy, the deadly disease that took her two sons." Now... How much longer those moms and their boys should suffer? It is imperative that FDA should approve deramiocel "even one day faster" to prevent more crying moms to lose their precious sons. https://www.youtube.com/watch?v=nQdOJIg8afo (8:53pm, Wednesday, California)
0 · Reply
HamBoneXoXo
HamBoneXoXo Jun. 26 at 3:48 AM
$CAPR Didn’t see much discussion on the four yr hope2 ole data: As shown below; one estimates 0.7 drop in drug effectiveness per yr translating to a drug utility of about 5 or at most 6 yrs continuous yrs. In other words, prescribing for life is not an option here as stabilization effects fade out by yr 6. Any comments?
7 · Reply
Coinbit
Coinbit Jun. 26 at 3:29 AM
$CAPR I am going to be buying every morning 10 shares at opening regardless the price till approval !!!! Shorts bring it on
0 · Reply
CAPRfanBoy
CAPRfanBoy Jun. 26 at 3:23 AM
$CAPR buying another 100 shares in the morning. Who else plans to buy?
0 · Reply
OKLM250
OKLM250 Jun. 26 at 3:21 AM
$CAPR EOD the same people falling for the nonsense articles and FUD post are the same people who would dump at 50. Real holders know what we are putting are money into; care about the goal of the company, saving the kids. CAPR TO THE MOON as always.
0 · Reply
CAPRfanBoy
CAPRfanBoy Jun. 26 at 2:59 AM
$CAPR Big couple months ahead of us boys. Lets have some fun and stay calm. We’ll look back a decade from now and realize how fun all this was even tho it’s been stressful. The “cult” lives strong! Leave a like if you are with me 😤
2 · Reply
MrsBelfort
MrsBelfort Jun. 26 at 2:59 AM
$CAPR Well said. He thinks CAPR "retail cult"will plead with him to change his mighty opinion. (And to my chagrin, some do!) The only conversation I am interested considering him would be the size of his orange jump suit , if it ever comes down to that.
1 · Reply
BioRich
BioRich Jun. 26 at 2:37 AM
@AZ89 Thanks for the question about $SRPT and their relationship with $RHHBY. As mentioned, I think that relationship is likely very strained. I'm not sure Buyout is on the table given their current relationship but do have a better idea for Sarepta's future. I think $SRPT Buys, or at least lucratively partners with, $CAPR. I think it's a win for both, although non-business-related many probably think that they aren't a good marriage. Financially and business-wise, it makes sense. One up and comer with a bright future ($CAPR) pairing with a damaged class leader ($SRPT). Depending on how they play it, they will be able to calm the storm around SRPT and give solid foundational support for CAPR as they navigate the FDA and commercial launch hurdles. Doug and Linda could become a Co-CEO power couple. What do you think about that idea? Follow/Subscribe for more thoughts and perspective. Let's make some money. Cheers!
2 · Reply
Drichman7
Drichman7 Jun. 26 at 2:33 AM
$SRPT see you all at $CAPR
0 · Reply
Chachi88
Chachi88 Jun. 26 at 2:31 AM
$CAPR So the SRPT product was supposed to generate $1.2B for the company this year. If we can get to that level of revenue, what do we expect the SP to be? Think we can generate a higher revenue number?
1 · Reply
TopStockStar
TopStockStar Jun. 26 at 2:27 AM
Hey $CAPR...
0 · Reply
Fenderstrat68
Fenderstrat68 Jun. 26 at 2:13 AM
$CAPR can we just all agree to make it back to $17 before mid July!? Come on
2 · Reply
satrasal
satrasal Jun. 26 at 1:43 AM
$CAPR @snowboy And related to Point 2, I'd ask about a dose escalation study. We know that 4x infusions vastly outperformed 1x. What happens to partial and non responders as you go to 8x or 12x, and what factors might predict response to escalation. For instance in the gemini vedolizumab trial in Ulcerative Colitis, there was no difference in response between 4 week and 8 week dosing and 40% of pats did not respond. But real world data later showed that pats with severe disease (as indicated by anti-tnf exposure) predicted that of the non responders, 1/2 achieved remission and another half achieved partial response on dose escalation.
1 · Reply
aricray
aricray Jun. 26 at 1:07 AM
$CAPR So the D gets approval for DMD, everyone cheers and, with a sly grin, the knowing investor recognizes that the big picture is the exosomes delivery platform and D's ability to regenerate ALL muscle fiber.
2 · Reply
StockScanners
StockScanners Jun. 26 at 1:04 AM
$CAPR Reached 10.48 lets go team
0 · Reply